Equibles does not estimate personal net worth.
Get an email with a short summary when DiaMedica Therapeutics Inc. publishes a filing, an earnings call transcript or a press release.
Get DMAC alertsScott Kellen is recorded as CFO at DiaMedica Therapeutics Inc. (DMAC). The proxy statement of DiaMedica Therapeutics Inc. reports total compensation of $1,229,520 for Scott Kellen in fiscal 2025, including a base salary of $408,500. Disclosed compensation is on record for 8 fiscal years. Scott Kellen has spoken on 24 earnings calls across 1 company, most recently for DiaMedica Therapeutics Inc. on November 13, 2026. DiaMedica Therapeutics Inc. is classified in the Biotechnology industry within the Healthcare sector. Other leadership on record at DiaMedica Therapeutics Inc. includes Rick Pauls (CEO and Board Member), James Parsons (Chairman), Charles Semba (Board Member) and 7 others.
“As of September 30, 2026, we had $34.9 million in cash, cash equivalents, and short-term investments, compared with $59.9 million at December 31, 2025. Current liabilities were $7.5 million, and working capital was $28 million at quarter-end, compared with $5.1 million and $55.5 million, respectively, at year-end 2025.”
“So, in walking through the financial results for the second quarter, as of June 30, 2026, our cash, cash equivalents, and short-term investments were $43.5 million.”
“We announced our first quarter 2026 financial results and filed our quarterly report on Form 10Q yesterday after the markets closed.”
“We announced our full-year financial results for 2025 and filed our annual report on Form 10-K yesterday. As of December 31st, 2025, our cash, cash equivalents, and short-term investments were $59.9 million.”
“As of September 30, 2025, our cash, cash equivalents, and short-term investments were $55.3 million. This compared to $30 million as of June 30, 2025, and $44.1 million as of our prior year-end.”
Biotechnology · Healthcare
CFO
Compensation components disclosed in company proxy statements. Amounts are nominal USD; total is the company-reported figure.
| Fiscal year | Company | Role | Salary | Total |
|---|---|---|---|---|
| 2025 | DiaMedica Therapeutics Inc. (DMAC) | Chief Financial Officer and Secretary | $408,500 | $1,229,520 |
| 2024 | DiaMedica Therapeutics Inc. (DMAC) | Chief Financial Officer and Secretary | $374,250 | $813,955 |
| 2023 | DiaMedica Therapeutics Inc. (DMAC) | Chief Financial Officer and Secretary | $352,750 | $632,215 |
| 2022 | DiaMedica Therapeutics Inc. (DMAC) | Chief Financial Officer and Secretary | $329,392 | $563,574 |
| 2021 | DiaMedica Therapeutics Inc. (DMAC) | Chief Financial Officer and Secretary | $286,211 | $546,720 |
| 2020 | DiaMedica Therapeutics Inc. (DMAC) | Chief Financial Officer and Secretary | $276,075 | $489,303 |
| 2019 | DiaMedica Therapeutics Inc. (DMAC) | Chief Financial Officer and Secretary | $262,500 | $677,807 |
| 2018 | DiaMedica Therapeutics Inc. (DMAC) | Chief Financial Officer and Secretary | $200,833 | $642,921 |
